BridgeBio Pharma, Inc. — Director's Dealing 2025

Aug 22, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-08-21

Reporting Person: Trimarchi Thomas (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-08-21	Common Stock	S	42237	$49.4846	Disposed	421081	Direct

Footnotes

F1: Represents the weighted average sale price of the shares sold from $49.08 to $49.77 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.